- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02112344
A Study of Intensity-modulated Radiotherapy in Patients With Squamous Cell Carcinoma of Unknown Primary (SCCUP) of the Head and Neck
A Phase I Study of Intensity-modulated Radiotherapy in Patients With Squamous Cell Carcinoma of Unknown Primary (SCCUP) of the Head and Neck
Squamous cell carcinoma of unknown primary (SCCUP) site metastatic to cervical lymph nodes at presentation is a relatively rare entity forming about 2% of all head and neck carcinomas.
Typically patients are treated with ipsilateral modified radical neck dissection (MRND) and post-operative radiotherapy (PORT) or chemoradiotherapy.
There is a lack of consensus on the radiotherapy target volumes that should be treated after neck dissection. The most common radiotherapy techniques are either unilateral cervical lymph node irradiation to achieve local control in the ipsilateral neck or TMI of the head and neck region with the aim of eradicating the primary and the microscopic neck disease.
Treatment of the ipsilateral hemi-neck alone is of low toxicity and may achieve local control in the cervical nodes. Potential occult primary sites in the head and neck mucosa, and any sub-clinical metastatic disease in the contralateral side of the neck are left untreated. If a primary tumour subsequently becomes apparent the previous radiotherapy may make further radiotherapy difficult to deliver.
Some groups recommend bilateral neck and total mucosal irradiation in this setting claiming improved local control. With conventional radiotherapy technique this is at the price of significant acute toxicity and chronic morbidity, mainly xerostomia with its associated complications and effects on quality of life (QOL).
Intensity modulated radiotherapy (IMRT) has been shown to reduce the dose to salivary gland tissue and consequently may reduce the incidence of xerostomia and improve quality of life (QOL) in head and neck cancer patients.
An analysis of parotid-sparing IMRT at the University of Michigan established a mean dose threshold for both stimulated (26 Gy), and unstimulated (24 Gy) saliva flow rates. For the same end-point (less than 25% of flow at baseline one year post radiation) Roesink et al established a TD50 of 39 Gy.
The investigators performed a planning study to assess the feasibility of IMRT to spare the parotid gland while delivering bilateral neck and TMI. The mean dose to the contralateral parotid gland using IMRT was below the threshold of 24 Gy for unstimulated salivary flow, predicting a fairly low risk of radiation induced xerostomia. The mean dose to the ipsilateral parotid gland was 32 Gy which was below the TD50 dose based on the Roesink data.
This study assesses the safety and tolerability of delivering IMRT in clinical practice to treat patients with SCCUP of the head and neck region, who require bilateral neck and pan-mucosal irradiation.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Squamous cell carcinomas metastatic to cervical lymph node with occult primary requiring bilateral neck and pan mucosal irradiation.
- Radiotherapy either as primary therapy or post-operative (adjuvant irradiation).
- Neoadjuvant and concomitant chemotherapy are permitted.
- All patients must be suitable to attend regular follow-up and undergo toxicity assessment.
- Stage T0, N1-3, M0 disease
- WHO Performance Status 0-1.
- Patient should have a negative PET/CT scan for a primary tumour.
Exclusion Criteria:
- Previous radiotherapy to the head and neck region
- Previous malignancy except non-melanoma skin cancer
- Previous or concurrent illness which in the investigators opinion would interfere with either completion of therapy or follow-up
- Prophylactic use of amifostine or pilocarpine is not allowed
- Brachytherapy is not allowed as part of the treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Total mucosal irradiation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of delivering IMRT
Time Frame: 7 weeks after starting radiotherapy
|
Feasibility of delivering IMRT in this setting i.e. all the patients completing the radiotherapy protocol without treatment breaks due to toxicity.
|
7 weeks after starting radiotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of acute dermatitis
Time Frame: 3 months after RT
|
Outcome measured at baseline, weeks 1-6 during RT.
Weeks 1-4 and 8 after RT.
|
3 months after RT
|
Incidence of >grade 1 late xerostomia
Time Frame: 5 years
|
Outcome measured at 3, 6, 12, 18, 24 months after RT.
|
5 years
|
Number of patients who do not relapse at the local site
Time Frame: 5 years
|
Local control assessed at 3, 6 months, then every 6 months to 5 years.
|
5 years
|
Overall survival
Time Frame: 5 years
|
Assessed at 3 and 6 months then every 6 months to 5 years.
|
5 years
|
Incidence of acute alopecia
Time Frame: 3 months after RT
|
Outcome measured at baseline, weeks 1-6 during RT.
Weeks 1-4 and 8 after RT.
|
3 months after RT
|
Incidence of >grade 1 acute dysphagia
Time Frame: 3 months after RT
|
Outcome measured at baseline, weeks 1-6 during RT.
Weeks 1-4 and 8 after RT.
|
3 months after RT
|
Incidence of > grade 1 acute mucositis
Time Frame: 3 months after RT
|
Outcome measured at baseline, weeks 1-6 during RT.
Weeks 1-4 and 8 after RT.
|
3 months after RT
|
Incidence of acute radiation induced pain
Time Frame: 3 months after RT
|
Outcome measured at baseline, weeks 1-6 during RT.
Weeks 1-4 and 8 after RT.
|
3 months after RT
|
Incidence of >grade 1 acute xerostomia
Time Frame: 3 months after RT
|
Outcome measured at baseline, weeks 1-6 during RT.
Weeks 1-4 and 8 after RT.
|
3 months after RT
|
Incidence of acute radiation induced fatigue
Time Frame: 3 months after RT
|
Outcome measured at baseline, weeks 1-6 during RT.
Weeks 1-4 and 8 after RT.
|
3 months after RT
|
Incidence of > grade 1 late dysphagia
Time Frame: 5 years after RT
|
Outcome measured at 3, 6, 12, 18, 24 months after RT.
|
5 years after RT
|
Incidence of late oesophageal stricture
Time Frame: 5 years after RT
|
Outcome measured at 3, 6, 12, 18, 24 months after RT.
|
5 years after RT
|
Incidence of >grade 1 late hoarse voice
Time Frame: 5 years after RT
|
Outcome measured at 3, 6, 12, 18, 24 months after RT.
|
5 years after RT
|
Incidence of late radiation induced neurological dysfunction
Time Frame: 5 years
|
Outcome measured at 3, 6, 12, 18, 24 months after RT.
|
5 years
|
Incidence of >grade1 late skin toxicity
Time Frame: 5 years after RT
|
Outcome measured at 3, 6, 12, 18, 24 months after RT.
|
5 years after RT
|
Collaborators and Investigators
Investigators
- Principal Investigator: Christopher M Nutting, PhD, Royal Marsden NHS Foundation Trust
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCR 2823
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
WepromNeptuneActive, not recruitingMetastatic Colorectal Cancer | Metastatic Head and Neck CancerFrance
Clinical Trials on IMRT
-
Cancer Institute and Hospital, Chinese Academy...UnknownSmall-cell Lung CancerChina
-
National Cancer Institute, EgyptActive, not recruiting
-
Sun Yat-sen UniversityActive, not recruitingQuality of Life | Mortality | Nasopharyngeal Neoplasms | ComplicationsChina
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedSexual Dysfunction | Prostate Cancer | Radiation Toxicity | Psychosocial Effects of Cancer and Its TreatmentUnited States, Canada
-
St. Jude Children's Research HospitalMayo ClinicTerminatedAbdominal NeuroblastomaUnited States
-
University of Michigan Rogel Cancer CenterTerminatedBreast CancerUnited States
-
Washington University School of MedicineTerminatedHead and Neck CancerUnited States
-
Alberta Health servicesCompleted
-
Jiangsu Cancer Institute & HospitalNot yet recruitingStage IVA Nasopharyngeal CarcinomaChina
-
Institute of Cancer Research, United KingdomCancer Research UKUnknownProstate CancerUnited Kingdom